ORPHA:213807
Leiomyosarcoma of the cervix uteri
Also known as: Cervical leiomyosarcoma
Publications
316
64.9th percentile
Trials
0
Interventional, condition-specific
Researchers
1,057
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Leiomyosarcoma of the cervix uteri is a rare, malignant mesenchymal tumor of smooth muscle origin, macroscopically appearing as a large, poorly circumscribed mass, often protruding from the cervical canal or expanding it circumferentially. The most common presenting symptoms are vaginal discharge or bleeding, pain in the lower abdomen and a bulky cervical mass. There is a reported tendency to metastatsize hematogenously, especially to the lungs, peritoneum, bones and the liver.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016283
- UMLS:C4289817
- NCIT:C128047
Additional Mondo synonyms (3)
cervical leiomyosarcoma · leiomyosarcoma of uterine cervix · uterine cervix leiomyosarcoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
316 matched papers (164 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 141 for broader category leiomyosarcoma
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
316
316 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
316 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
164 in the last 10 years · medium confidence · 64.9th percentile (publications denominator)
Phrase hits: 316 · MeSH hits: 0
Who's working on it?
1,057
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Balodis A3 papers · 2026
Institute of Diagnostic Radiology, Pauls Stradins Clinical University Hospital, 13 Pilsonu Street, LV-1002 Riga, Latvia
Papers in Europe PMC - 02Mahmajeva O3 papers · 2026
Institute of Pathology, Pauls Stradins Clinical University Hospital, 13 Pilsonu Street, LV-1002 Riga, Latvia
Papers in Europe PMC - 03Mikijanska M3 papers · 2026
Institute of Diagnostic Radiology, Pauls Stradins Clinical University Hospital, 13 Pilsonu Street, LV-1002 Riga, Latvia
Papers in Europe PMC - 04Özütemiz C3 papers · 2026
Department of Radiology, University of Minnesota, Minneapolis, MN 55455, USA
Papers in Europe PMC - 05Rate E3 papers · 2026
Clinic of Otolaryngology, Pauls Stradins Clinical University Hospital, 13 Pilsonu Street, LV-1002 Riga, Latvia
Papers in Europe PMC - 06Tumelkans R3 papers · 2026
Faculty of Medicine, Riga Stradins University, 16 Dzirciema Street, LV-1007 Riga, Latvia
Papers in Europe PMC - 07Abeillon J2 papers · 2025
Hospices Civils de Lyon, Hôpital Louis Pradel, Service d'Endocrinologie, Bron, France.
Papers in Europe PMC - 08Albert A2 papers · 2020
Department of Radiation Oncology, University of Mississippi Medical Center, Jackson, MS, USA. ashley.grv@gmail.com.
Papers in Europe PMC - 09Benfadil D2 papers · 2025
ENT and Head and Neck Surgery Department, University Hospital Center Mohammed VI, Faculty of Medicine and Pharmacy, Mohammed First University, Oujda, Morocco.
Papers in Europe PMC - 10Cacciotti G2 papers · 2023
Department of Neurosurgery, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 141 trials are registered for leiomyosarcoma, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
medium confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
141 interventional trials matched leiomyosarcoma, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: leiomyosarcoma
141
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07516925·RECRUITING·A Study of Ivonescimab in People With Leiomyosarcoma
Conditions: Leiomyosarcoma·Matched via name phrase
- NCT04055220·RECRUITING·Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Conditions: Bone Sarcoma · Osteosarcoma · Ewing Sarcoma · Chondrosarcoma·Matched via name phrase
- NCT02275286·RECRUITING·Trabectedin Plus Radiotherapy in Soft Tissue Sarcoma Patients
Conditions: Liposarcoma, Myxoid · Sarcoma, Soft Tissue · Leiomyosarcoma · Liposarcoma·Matched via name phrase
- NCT06849986·RECRUITING·IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
Conditions: Soft Tissue Sarcomas · Angiosarcoma · Fibrosarcoma · Leiomyosarcoma·Matched via name phrase
- NCT07076186·RECRUITING·Phase II Decentralized Pragmatic Trial of Adjuvant Doxorubicin - Trabectedin Chemotherapy in uLMS
Conditions: Uterine Leiomyosarcoma·Matched via name phrase
- NCT06528769·RECRUITING·Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Conditions: Leiomyosarcoma · Sarcoma·Matched via name phrase
- NCT06957431·RECRUITING·Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Conditions: Advanced Leiomyosarcoma · Adipocytic Sarcoma · Advanced Liposarcoma·Matched via name phrase
- NCT06239272·RECRUITING·NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Conditions: Adipocytic Neoplasm · Liposarcoma · Atypical Fibroxanthoma · Angiomatoid Fibrous Histiocytoma·Matched via name phrase
- NCT06524583·RECRUITING·Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour
Conditions: Leiomyosarcoma Uterus·Matched via name phrase
- NCT07467772·RECRUITING·Ph 2 Elacestrant in ER Positive Uterine Sarcomas
Conditions: Uterine Sarcoma · Uterine Leiomyosarcoma · Endometrial Stromal Sarcoma · ESS·Matched via name phrase
- NCT04535271·RECRUITING·Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
Conditions: Leiomyosarcoma·Matched via name phrase
- NCT07405346·ENROLLING BY INVITATION·A Trial for Advanced Leiomyosarcoma With Human Organoid-guided Personalized Efficacy
Conditions: Advanced Leiomyosarcoma·Matched via name phrase
- NCT06308419·RECRUITING·A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
Conditions: Leiomyosarcoma · Soft-tissue Sarcomas·Matched via name phrase
- NCT06638931·RECRUITING·Agnostic Therapy in Rare Solid Tumors
Conditions: Urachal Cancer · Parathyroid Carcinoma · Fibrolamellar Carcinoma · Angiosarcoma·Matched via name phrase
- NCT06498648·RECRUITING·Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Conditions: Advanced Dedifferentiated Liposarcoma · Advanced Leiomyosarcoma · Advanced Soft Tissue Sarcoma · Metastatic Dedifferentiated Liposarcoma·Matched via name phrase
General rare disease registries you may be eligible for
These studies enroll across many rare conditions. They are not counted as evidence that anyone is studying this specific disease.
- NCT01793168·RECRUITING·Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Conditions: Rare Disorders · Undiagnosed Disorders · Disorders of Unknown Prevalence · Cornelia De Lange Syndrome
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Leiomyosarcoma of the cervix uteri — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Leiomyosarcoma of the cervix uteri" OR "Leiomyosarcoma of cervix uteri" OR "Cervical leiomyosarcoma" OR "leiomyosarcoma of uterine cervix" OR "leiomyosarcoma of the uterine cervix" OR "uterine cervix leiomyosarcoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Leiomyosarcoma of the cervix uteri" OR "Leiomyosarcoma of cervix uteri" OR "Cervical leiomyosarcoma" OR "leiomyosarcoma of uterine cervix" OR "leiomyosarcoma of the uterine cervix" OR "uterine cervix leiomyosarcoma"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"leiomyosarcoma"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (316) is high for prevalence class "<1 / 1 000 000" — confidence capped at medium
Ingested 2026-07-27T09:39:41.057Z
